|
Volumn 122, Issue 8, 2008, Pages 1716-1721
|
Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CA 125 ANTIGEN;
FAS ANTIGEN;
PLATINUM DERIVATIVE;
TUMOR MARKER;
ADJUVANT CHEMOTHERAPY;
ADULT;
ARTICLE;
BLOOD;
CARCINOMA;
DISEASE FREE SURVIVAL;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FEMALE;
HUMAN;
MIDDLE AGED;
OVARY TUMOR;
PREDICTION AND FORECASTING;
PROPORTIONAL HAZARDS MODEL;
ROC CURVE;
SENSITIVITY AND SPECIFICITY;
TREATMENT OUTCOME;
ADULT;
ANTIGENS, CD95;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CA-125 ANTIGEN;
CARCINOMA;
CHEMOTHERAPY, ADJUVANT;
DISEASE-FREE SURVIVAL;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
FEMALE;
HUMANS;
MIDDLE AGED;
OVARIAN NEOPLASMS;
PLATINUM COMPOUNDS;
PREDICTIVE VALUE OF TESTS;
PROPORTIONAL HAZARDS MODELS;
ROC CURVE;
SENSITIVITY AND SPECIFICITY;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 40349100313
PISSN: None
EISSN: 10970215
Source Type: Journal
DOI: 10.1002/ijc.23213 Document Type: Article |
Times cited : (15)
|
References (0)
|